Literature DB >> 7389252

Propranolol dynamics in thyrotoxicosis.

J Feely, I H Stevenson, J Crooks.   

Abstract

Twenty-five thyrotoxic patients were treated with propranolol (160 mg/day) for 1 to 2 wk. Although the response to therapy varied there was a reduction (p less than 0.001) in supine and exercise heart rates and in sitting pulse rate. Serum triiodothyronine (T3) fell (p less than 0.001) and serum thyroxine did not change during propranolol therapy. Plasma propranolol levels before assessment varied from 5 to 121 ng/ml, and there were positive correlations between them and percentage reduction in exercise (r = 0.78, p less than 0.001) and resting (r = 0.61, n = 14, p less than 0.05) heart rates, percentage reduction in sitting pulse rate (r = 0.73, p less than 0.001), and the percentage reduction in serum T3 (r = 0.59, n = 23, p less than 0.01). Although weight loss ceased in the group as a whole the degree of continued weight loss or weight gain in individual patients was also related to plasma propranolol concentration (r = 0.61, p less than 0.01). The plasma propranolol level correlated (r = 0.62, p less than 0.01) with thyrotoxicosis therapeutic index. There was no correlation between degress of subjective improvement and plasma propranolol level.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389252     DOI: 10.1038/clpt.1980.128

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

2.  Variability of beta-blocker pharmacokinetics in young volunteers.

Authors:  D B Jack; C P Quarterman; R Zaman; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Nadolol in thyrotoxicosis.

Authors:  N R Peden; T E Isles; I H Stevenson; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 4.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

5.  Pharmacokinetics of propranolol and sotalol in hyperthyroidism.

Authors:  A Aro; M Anttila; T Korhonen; H Sundquist
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 6.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Authors:  Michael J Grant; Roy S Herbst; Sarah B Goldberg
Journal:  Nat Rev Clin Oncol       Date:  2021-06-24       Impact factor: 66.675

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.